- Home
- EDSA vs AEI Comparison
EDSA vs AEI Comparison
Compare EDSA & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- AEI
- Stock Information
- Founded
- EDSA 2015
- AEI 2014
- Country
- EDSA Canada
- AEI United States
- Employees
- EDSA N/A
- AEI N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- AEI Building operators
- Sector
- EDSA Health Care
- AEI Real Estate
- Exchange
- EDSA Nasdaq
- AEI Nasdaq
- Market Cap
- EDSA 13.7M
- AEI 13.4M
- IPO Year
- EDSA N/A
- AEI N/A
- Fundamental
- Price
- EDSA $4.32
- AEI $1.50
- Analyst Decision
- EDSA Strong Buy
- AEI
- Analyst Count
- EDSA 2
- AEI 0
- Target Price
- EDSA $39.00
- AEI N/A
- AVG Volume (30 Days)
- EDSA 8.4K
- AEI 64.9K
- Earning Date
- EDSA 08-09-2024
- AEI 11-12-2024
- Dividend Yield
- EDSA N/A
- AEI N/A
- EPS Growth
- EDSA N/A
- AEI N/A
- EPS
- EDSA N/A
- AEI N/A
- Revenue
- EDSA N/A
- AEI $9,220,976.00
- Revenue This Year
- EDSA N/A
- AEI N/A
- Revenue Next Year
- EDSA N/A
- AEI N/A
- P/E Ratio
- EDSA N/A
- AEI N/A
- Revenue Growth
- EDSA N/A
- AEI N/A
- 52 Week Low
- EDSA $2.46
- AEI $0.46
- 52 Week High
- EDSA $8.33
- AEI $2.05
- Technical
- Relative Strength Index (RSI)
- EDSA 53.46
- AEI 58.57
- Support Level
- EDSA $4.22
- AEI $1.04
- Resistance Level
- EDSA $5.00
- AEI $1.76
- Average True Range (ATR)
- EDSA 0.25
- AEI 0.19
- MACD
- EDSA 0.04
- AEI 0.05
- Stochastic Oscillator
- EDSA 53.06
- AEI 63.67
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.
About AEI Alset Inc. (TX)
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.